
  
    
      
        Background
        Acute pain has been studied in single dose designs first
        proposed by <ENAMEX TYPE="ORGANIZATION">Beecher</ENAMEX> and <ENAMEX TYPE="PER_DESC">colleagues</ENAMEX> [ <NUMEX TYPE="CARDINAL">1 2</NUMEX> ] and formalized
        by <ENAMEX TYPE="ORGANIZATION">Houde</ENAMEX> and <ENAMEX TYPE="ORGANIZATION">Wallenstein</ENAMEX> [ <ENAMEX TYPE="LAW">3</ENAMEX> ] . The problem with single
        trials is that while they can demonstrate statistical
        superiority of analgesic over placebo, variation because of
        <ENAMEX TYPE="ORGANIZATION">random</ENAMEX> chance means that, if small, they provide a poor
        estimate of the size of the analgesic effect [ <ENAMEX TYPE="LAW">4</ENAMEX> ] .
        Combining results from clinically homogeneous trials in a
        <ENAMEX TYPE="ORGANIZATION">meta</ENAMEX>-analysis gives an accurate estimate of the extent of
        the analgesic effect when sufficient numbers of patients
        have been randomized [ <NUMEX TYPE="CARDINAL">4 5</NUMEX> ] .
        Clinical trials in acute pain normally last <TIMEX TYPE="TIME">four to six</TIMEX>
        <TIMEX TYPE="TIME">hours</TIMEX>, because that is the duration of effect for most
        analgesics, whether injected or as <ENAMEX TYPE="SUBSTANCE">tablets</ENAMEX>, and for simple
        analgesics, <ENAMEX TYPE="ORGANIZATION">NSAIDs</ENAMEX> or opioids. <ENAMEX TYPE="ORGANIZATION">Meta</ENAMEX>-analysis in acute pain
        has concentrated on the use of the area under the total
        pain relief versus time curve (TOTPAR), dichotomized into
        at least <NUMEX TYPE="PERCENT">50%</NUMEX> pain relief or not [ <ENAMEX TYPE="LAW">6</ENAMEX> ] . It is not
        necessarily the only measure available or the most
        relevant. The precedent exists at a primary research level
        for adopting remedication as an outcome. <ENAMEX TYPE="ORGANIZATION">Bullingham</ENAMEX> and
        <ENAMEX TYPE="PER_DESC">colleagues</ENAMEX> [ <ENAMEX TYPE="LAW">7</ENAMEX> ] and <ENAMEX TYPE="ORGANIZATION">Gibb</ENAMEX> and <ENAMEX TYPE="PER_DESC">colleagues</ENAMEX> [ <ENAMEX TYPE="LAW">8</ENAMEX> ] explored the
        measure of re-<ENAMEX TYPE="SUBSTANCE">medication</ENAMEX> in post-surgical <ENAMEX TYPE="PER_DESC">patients</ENAMEX> subject
        to multiple dosing. A 'rescue factor' design was refined to
        demonstrate both analgesic <ENAMEX TYPE="SUBSTANCE">efficacy</ENAMEX> and assay sensitivity.
        [ <ENAMEX TYPE="LAW">9</ENAMEX> ] . <ENAMEX TYPE="ORGANIZATION">Farrar</ENAMEX> and <ENAMEX TYPE="PER_DESC">colleagues</ENAMEX> [ <TIMEX TYPE="DATE">10</TIMEX> ] extrapolated from
        <ENAMEX TYPE="ORGANIZATION">re</ENAMEX>-medication data in an effort to both define and
        demonstrate analgesic <ENAMEX TYPE="SUBSTANCE">efficacy</ENAMEX>.
        Despite these efforts, time to remedication has never
        become a standard outcome in analgesic trials. <NUMEX TYPE="CARDINAL">One</NUMEX> reason
        for this might simply be the similarity in duration between
        commonly used analgesics. For rofecoxib, this might be
        different. In <NUMEX TYPE="QUANTITY">arthritis 12.5 mg or 25 mg</NUMEX> of rofecoxib is
        given as a single dose once a day to control pain. The
        acute pain dose of <NUMEX TYPE="CARDINAL">50</NUMEX> mg is claimed to have prolonged
        analgesic activity [ <TIMEX TYPE="DATE">11</TIMEX> ] .
        The purpose of this systematic review and meta-analysis
        of rofecoxib in acute pain was threefold. <NUMEX TYPE="ORDINAL">First</NUMEX> to examine
        all acute pain studies of analgesic <ENAMEX TYPE="SUBSTANCE">efficacy</ENAMEX> in <ENAMEX TYPE="PER_DESC">adults</ENAMEX> over
        <TIMEX TYPE="DATE">six hours</TIMEX> for comparison with other analgesics in acute
        pain. <NUMEX TYPE="ORDINAL">Second</NUMEX> to examine the amount and quality of the
        evidence presented on extended duration of analgesia. <NUMEX TYPE="ORDINAL">Third</NUMEX>
        to examine the quality and quantity of evidence on adverse
        events.
      
      
        Methods
        <ENAMEX TYPE="ORGANIZATION">QUORUM</ENAMEX> guidelines were followed [ <TIMEX TYPE="DATE">12</TIMEX> ] . Possible
        studies for inclusion were sought through searching the
        <ENAMEX TYPE="ORGANIZATION">Cochrane Library</ENAMEX> (issue <TIMEX TYPE="DATE">4, 2001</TIMEX>), <ENAMEX TYPE="LAW">Biological Abstracts</ENAMEX>
        (<TIMEX TYPE="DATE">March 2002</TIMEX>), <ENAMEX TYPE="ORGANIZATION">MEDLINE</ENAMEX> (<TIMEX TYPE="DATE">March 2002</TIMEX>) and <ENAMEX TYPE="PERSON">PubMed</ENAMEX> (<TIMEX TYPE="DATE">March 2002</TIMEX>)
        using rofecoxib as a free text term. The search strategy
        used is detailed in <ENAMEX TYPE="FAC">Additional File 1</ENAMEX>. Abstracts were
        examined for possible inclusion if they were randomized
        trials conducted in an acute pain setting, used rofecoxib
        and a placebo or active comparator. <ENAMEX TYPE="ORGANIZATION">Reference</ENAMEX> lists and
        review articles were examined for possible additional
        <ENAMEX TYPE="PERSON">references</ENAMEX>, and in-house <ENAMEX TYPE="PER_DESC">databases</ENAMEX> were also searched for
        papers.
        Criteria for inclusion for postoperative pain were: full
        <ENAMEX TYPE="ORGANIZATION">journal</ENAMEX> publication, randomized controlled trials which
        included single dose treatment <ENAMEX TYPE="ORG_DESC">groups</ENAMEX> of oral rofecoxib and
        <ENAMEX TYPE="PERSON">placebo</ENAMEX>, double blind design, baseline postoperative pain
        of moderate to severe intensity, <ENAMEX TYPE="PER_DESC">patients</ENAMEX> over <TIMEX TYPE="DATE">15 years</TIMEX> of
        age, <NUMEX TYPE="CARDINAL">at least 10</NUMEX> <ENAMEX TYPE="PER_DESC">patients</ENAMEX> per <ENAMEX TYPE="ORG_DESC">group</ENAMEX>, and the pain outcome
        measures of total pain relief (TOTPAR) or summed pain
        intensity difference (SPID) over <TIMEX TYPE="TIME">4-6 hours</TIMEX> or sufficient
        <ENAMEX TYPE="ORGANIZATION">data</ENAMEX> to allow their calculation. Pain measures allowed for
        the calculation of <ENAMEX TYPE="ORGANIZATION">TOTPAR</ENAMEX> or SPID were a standard <NUMEX TYPE="CARDINAL">five</NUMEX>
        point pain relief scale (none, slight, moderate, good,
        complete), a standard <NUMEX TYPE="CARDINAL">four</NUMEX> point pain intensity scale
        (none, mild, moderate, severe) or a standard visual
        analogue scale (VAS) for pain relief or pain intensity.
        Also of interest was information on the time to
        <ENAMEX TYPE="ORGANIZATION">remedication</ENAMEX>. For adverse events, the primary outcome
        sought was the proportion of <ENAMEX TYPE="PER_DESC">patients</ENAMEX> experiencing any
        adverse event, with secondary outcomes of patients
        experiencing particular adverse events. Although adverse
        events are often reported inconsistently in acute pain
        trials [ <TIMEX TYPE="DATE">13</TIMEX> ] , the outcome of any patient experiencing any
        adverse event was the least inconsistently reported.
        Each report which could possibly be described as a
        <ENAMEX TYPE="ORG_DESC">randomized</ENAMEX> controlled trial was read independently by at
        least <NUMEX TYPE="CARDINAL">three</NUMEX> <ENAMEX TYPE="PER_DESC">authors</ENAMEX> and scored using a commonly-used three
        <ENAMEX TYPE="CONTACT_INFO">item, 1-5</ENAMEX> score, quality scale [ <TIMEX TYPE="DATE">14</TIMEX> ] . Consensus was then
        achieved. The maximum score of an included study was <NUMEX TYPE="CARDINAL">5</NUMEX> and
        the minimum score was <NUMEX TYPE="CARDINAL">2</NUMEX>. <ENAMEX TYPE="PER_DESC">Authors</ENAMEX> were not blinded because
        they already knew the literature.
        For each trial, mean <ENAMEX TYPE="ORGANIZATION">TOTPAR</ENAMEX>, <ENAMEX TYPE="ORGANIZATION">SPID</ENAMEX>, <ENAMEX TYPE="ORGANIZATION">VASTOTPAR</ENAMEX> or VASSPID
        values for each treatment <ENAMEX TYPE="ORG_DESC">group</ENAMEX> were converted to
        <NUMEX TYPE="PERCENT">%</NUMEX>maxTOTPAR by <ENAMEX TYPE="ORG_DESC">division</ENAMEX> into the calculated maximum value [
        <NUMEX TYPE="CARDINAL">15</NUMEX> ] . The proportion of <ENAMEX TYPE="PER_DESC">patients</ENAMEX> in each treatment group
        who achieved at least <NUMEX TYPE="PERCENT">50%</NUMEX>maxTOTPAR was calculated using
        valid equations [ <NUMEX TYPE="CARDINAL">16 17 18</NUMEX> ] . The number of patients
        randomized was taken as the basis for calculations, to
        produce an intention to treat analysis. The number of
        <ENAMEX TYPE="PER_DESC">patients</ENAMEX> with <NUMEX TYPE="PERCENT">at least 50%</NUMEX>maxTOTPAR was then used to
        calculate relative benefit and <ENAMEX TYPE="ORGANIZATION">NNT</ENAMEX> for rofecoxib versus
        <ENAMEX TYPE="PERSON">placebo</ENAMEX>. The same methods were used for adverse events.
        Relative benefit and relative risk estimates were
        calculated with <NUMEX TYPE="PERCENT">95%</NUMEX> confidence intervals using a fixed
        <ENAMEX TYPE="PRODUCT">effects</ENAMEX> model [ <TIMEX TYPE="DATE">19</TIMEX> ] . <ENAMEX TYPE="ORGANIZATION">Heterogeneity</ENAMEX> tests were not used as
        they have previously been shown to be unhelpful [ <NUMEX TYPE="CARDINAL">20 21</NUMEX> ] ,
        though homogeneity was examined visually [ <TIMEX TYPE="DATE">22</TIMEX> ] .
        Publication bias was not assessed using funnel plots as
        these tests have been shown to be unhelpful [ <NUMEX TYPE="CARDINAL">23 24</NUMEX> ] . The
        number needed to treat or harm (<ENAMEX TYPE="ORGANIZATION">NNT</ENAMEX> and <ENAMEX TYPE="ORGANIZATION">NNH</ENAMEX>) with
        confidence intervals was calculated by the method of <ENAMEX TYPE="ORGANIZATION">Cook</ENAMEX>
        and <ENAMEX TYPE="ORGANIZATION">Sackett</ENAMEX> [ <TIMEX TYPE="DATE">25</TIMEX> ] from the sum of all events and patients
        for treatment and placebo. Cumulative calculation of <ENAMEX TYPE="ORGANIZATION">NNT</ENAMEX> [
        <NUMEX TYPE="CARDINAL">5</NUMEX> ] was performed by adding studies by <TIMEX TYPE="DATE">year</TIMEX> of publication,
        and alphabetically within <TIMEX TYPE="DATE">a year</TIMEX>.
        Relative benefit or risk was considered to be
        statistically significant when the <NUMEX TYPE="PERCENT">95%</NUMEX> confidence interval
        did not include <NUMEX TYPE="CARDINAL">1</NUMEX>. <ENAMEX TYPE="ORGANIZATION">NNT</ENAMEX> or <ENAMEX TYPE="ORGANIZATION">NNH</ENAMEX> values were only calculated
        when the relative risk or benefit was statistically
        significant, and are reported with the <NUMEX TYPE="PERCENT">95%</NUMEX> confidence
        interval. Calculations were performed using <ENAMEX TYPE="ORGANIZATION">Microsoft Excel</ENAMEX>
        <TIMEX TYPE="DATE">2001</TIMEX> on a <ENAMEX TYPE="ORGANIZATION">Power Macintosh</ENAMEX> <ENAMEX TYPE="PRODUCT">G4</ENAMEX>.
        Additional file 1
        Search strategy
        Click here for file
      
      
        Results
        
          At least <NUMEX TYPE="PERCENT">50%</NUMEX> pain relief
          All <NUMEX TYPE="CARDINAL">five</NUMEX> trials gave or allowed the calculation of
          <TIMEX TYPE="DATE">six-hour</TIMEX> TOTPAR and the derivation of the number of
          <ENAMEX TYPE="PER_DESC">patients</ENAMEX> with <NUMEX TYPE="PERCENT">at least 50%</NUMEX>maxTOTPAR. There was good
          agreement between the <NUMEX TYPE="CARDINAL">five</NUMEX> studies (Figure <NUMEX TYPE="CARDINAL">1</NUMEX>). Overall
          <NUMEX TYPE="CARDINAL">252/464</NUMEX> <ENAMEX TYPE="PER_DESC">patients</ENAMEX> (<NUMEX TYPE="PERCENT">54%</NUMEX>) given rofecoxib <NUMEX TYPE="CARDINAL">50</NUMEX> <ENAMEX TYPE="PER_DESC">mg</ENAMEX> had at least
          <NUMEX TYPE="PERCENT">50%</NUMEX> maxTOTPAR over <TIMEX TYPE="TIME">six hours</TIMEX>, compared with <NUMEX TYPE="CARDINAL">24/211</NUMEX>
          <ENAMEX TYPE="PER_DESC">patients</ENAMEX> (<NUMEX TYPE="PERCENT">11%</NUMEX>) with placebo. The <ENAMEX TYPE="ORGANIZATION">NNT</ENAMEX> for one <ENAMEX TYPE="PER_DESC">patient</ENAMEX> to
          have <NUMEX TYPE="CARDINAL">at least half</NUMEX> pain relief over <TIMEX TYPE="TIME">six hours</TIMEX> was <NUMEX TYPE="CARDINAL">2.3</NUMEX>
          (<NUMEX TYPE="MONEY">2.0 to 2.6</NUMEX>) (<ENAMEX TYPE="PRODUCT">Table 1</ENAMEX>). Cumulative meta-analysis of the
          <NUMEX TYPE="CARDINAL">five</NUMEX> trials (Figure <NUMEX TYPE="CARDINAL">2</NUMEX>) shows that the <NUMEX TYPE="PERCENT">95%</NUMEX> confidence
          interval of the calculated <ENAMEX TYPE="ORGANIZATION">NNT</ENAMEX> fell within <TIMEX TYPE="TIME">Â± 0.5 NNT</TIMEX> of
          the overall mean (<NUMEX TYPE="MONEY">1.8 to 2.8</NUMEX>) when <NUMEX TYPE="CARDINAL">500</NUMEX> <ENAMEX TYPE="PER_DESC">patients</ENAMEX> had been
          <ENAMEX TYPE="ORGANIZATION">randomized</ENAMEX>.
        
        
          Remedication time
          Onset of analgesia with rofecoxib <NUMEX TYPE="CARDINAL">50</NUMEX> <ENAMEX TYPE="PER_DESC">mg</ENAMEX> appeared to be
          generally the same as with comparator analgesics. Trials
          tried to discourage remedication within <TIMEX TYPE="TIME">90 minutes</TIMEX>, and
          <NUMEX TYPE="CARDINAL">two</NUMEX> <ENAMEX TYPE="PER_DESC">patients</ENAMEX> in <NUMEX TYPE="CARDINAL">one</NUMEX> trial were excluded because they
          <ENAMEX TYPE="ORGANIZATION">remedicated</ENAMEX> within <TIMEX TYPE="TIME">90 minutes</TIMEX>, <NUMEX TYPE="CARDINAL">one</NUMEX> on placebo and <NUMEX TYPE="CARDINAL">one</NUMEX> on
          rofecoxib <NUMEX TYPE="CARDINAL">50</NUMEX> <ENAMEX TYPE="PER_DESC">mg</ENAMEX> [ <TIMEX TYPE="DATE">26</TIMEX> ] . This was not reported
          consistently ( <ENAMEX TYPE="PRODUCT">Additional File 3</ENAMEX>). The percentage of
          <ENAMEX TYPE="PER_DESC">patients remedicating</ENAMEX> within <TIMEX TYPE="TIME">two hours</TIMEX> was given in one
          study [ <TIMEX TYPE="DATE">26</TIMEX> ] , and within <TIMEX TYPE="TIME">24 hours</TIMEX> in <NUMEX TYPE="CARDINAL">two</NUMEX> [ <NUMEX TYPE="CARDINAL">11 27</NUMEX> ] .
          <NUMEX TYPE="CARDINAL">Only one</NUMEX> study (.( [ <TIMEX TYPE="DATE">27</TIMEX> ] gave cumulative remedication
          rates over the duration of the study. Median time to
          remedication was given in <NUMEX TYPE="CARDINAL">three</NUMEX> studies [ <NUMEX TYPE="CARDINAL">11 27 28</NUMEX> ] ,
          and this allowed the calculation of a mean of the three
          trials weighted by the number of <ENAMEX TYPE="PER_DESC">patients</ENAMEX>. For placebo
          the weighted mean time to remedication from <NUMEX TYPE="CARDINAL">126</NUMEX> <ENAMEX TYPE="PER_DESC">patients</ENAMEX>
          in <NUMEX TYPE="CARDINAL">three</NUMEX> trials was <TIMEX TYPE="TIME">1.9 hours</TIMEX>. For rofecoxib <NUMEX TYPE="CARDINAL">50</NUMEX> mg the
          weighted mean time to remedication from <NUMEX TYPE="CARDINAL">322</NUMEX> <ENAMEX TYPE="PER_DESC">patients</ENAMEX> in
          <NUMEX TYPE="CARDINAL">three</NUMEX> trials was <TIMEX TYPE="TIME">13.6 hours</TIMEX>. For ibuprofen <NUMEX TYPE="CARDINAL">400</NUMEX> mg the
          weighted mean time to remedication from <NUMEX TYPE="CARDINAL">97</NUMEX> <ENAMEX TYPE="PER_DESC">patients</ENAMEX> in
          <NUMEX TYPE="CARDINAL">two</NUMEX> trials was <TIMEX TYPE="TIME">7.4 hours</TIMEX>.
        
        
          Adverse events
          Adverse events were not reported consistently (
          Additional File <NUMEX TYPE="CARDINAL">3</NUMEX>). <NUMEX TYPE="CARDINAL">Two</NUMEX> trials reported the proportion of
          <ENAMEX TYPE="PER_DESC">patients</ENAMEX> having any adverse event. An adverse event was
          reported by <NUMEX TYPE="PERCENT">33%</NUMEX> of <ENAMEX TYPE="PER_DESC">patients</ENAMEX> on placebo and <NUMEX TYPE="PERCENT">28%</NUMEX> of those
          on <TIMEX TYPE="DATE">rofecoxib</TIMEX> <NUMEX TYPE="MONEY">50 mg</NUMEX> (not significantly different, <ENAMEX TYPE="PRODUCT">Table</ENAMEX>
          <NUMEX TYPE="CARDINAL">1</NUMEX>). Nausea and vomiting were reported separately in <TIMEX TYPE="TIME">three</TIMEX>
          <ENAMEX TYPE="ORGANIZATION">dental</ENAMEX> trials, and both occurred significantly less
          frequently with rofecoxib <NUMEX TYPE="CARDINAL">50</NUMEX> mg than with placebo (<ENAMEX TYPE="PRODUCT">Table</ENAMEX>
          <NUMEX TYPE="CARDINAL">1</NUMEX>). For both there were negative numbers needed to harm
          (-<NUMEX TYPE="CARDINAL">11</NUMEX> and <NUMEX TYPE="PERCENT">-12</NUMEX> respectively), showing that for every <NUMEX TYPE="CARDINAL">11</NUMEX> or
          <NUMEX TYPE="CARDINAL">12</NUMEX> <ENAMEX TYPE="PER_DESC">patients</ENAMEX> given rofecoxib, <NUMEX TYPE="CARDINAL">one</NUMEX> fewer was nauseous or
          vomited than with placebo. There were few events, though,
          with only <NUMEX TYPE="CARDINAL">44</NUMEX> nauseated <ENAMEX TYPE="PER_DESC">patients</ENAMEX> and <NUMEX TYPE="CARDINAL">only 27</NUMEX> who vomited
          in the <NUMEX TYPE="CARDINAL">three</NUMEX> trials of rofecoxib <NUMEX TYPE="CARDINAL">50</NUMEX> <ENAMEX TYPE="PER_DESC">mg</ENAMEX> comparable with <NUMEX TYPE="CARDINAL">34</NUMEX>
          nauseated <ENAMEX TYPE="PER_DESC">patients</ENAMEX> and <NUMEX TYPE="CARDINAL">only 22</NUMEX> who vomited in the two
          trials of ibuprofen <NUMEX TYPE="CARDINAL">400</NUMEX> mg.
        
      
      
        Discussion
        The <NUMEX TYPE="CARDINAL">five</NUMEX> included studies were of generally high
        reporting quality (quality scores of <NUMEX TYPE="CARDINAL">4</NUMEX> or <NUMEX TYPE="MONEY">5</NUMEX>), known to be
        <ENAMEX TYPE="ORGANIZATION">associated</ENAMEX> with minimal reporting bias [ <NUMEX TYPE="CARDINAL">30 31</NUMEX> ] . They all
        had a placebo control, used standardized pain intensity and
        relief scores in adult <ENAMEX TYPE="PER_DESC">patients</ENAMEX> with established pain of
        moderate or severe intensity, and measured outcomes over at
        <TIMEX TYPE="TIME">least six hours</TIMEX>. The pain models, <NUMEX TYPE="ORDINAL">third</NUMEX> molar dental
        <ENAMEX TYPE="PERSON">extraction</ENAMEX> and orthopaedic surgery, are commonly used in
        research and choice of <ENAMEX TYPE="PRODUCT_DESC">model</ENAMEX> does not appear to influence
        results in single-dose analgesic studies when <ENAMEX TYPE="PER_DESC">patients</ENAMEX> are
        able to take oral <ENAMEX TYPE="SUBSTANCE">medication</ENAMEX> [ <TIMEX TYPE="DATE">13</TIMEX> ] . Comparison of
        rofecoxib <NUMEX TYPE="CARDINAL">50</NUMEX> mg with other analgesics over <TIMEX TYPE="TIME">six hours</TIMEX> is
        legitimate, because the same outcome was measured in the
        same way in the same <ENAMEX TYPE="PER_DESC">patients</ENAMEX> over the same period of time,
        and with same comparator.
        Compared with placebo, the <ENAMEX TYPE="ORGANIZATION">NNT</ENAMEX> for <NUMEX TYPE="PERCENT">at least 50%</NUMEX> pain
        relief over <TIMEX TYPE="TIME">six hours</TIMEX> was <NUMEX TYPE="MONEY">2.3</NUMEX> (<NUMEX TYPE="MONEY">2.0 to 2.6</NUMEX>). Table 2collects
        <ENAMEX TYPE="ORGANIZATION">NNTs</ENAMEX> for a number of common oral analgesics and
        intramuscular morphine from recent meta-analyses [ <NUMEX TYPE="CARDINAL">32 13</NUMEX> ]
        and unpublished updates of other published <ENAMEX TYPE="PERSON">Cochrane</ENAMEX> reviews
        [ <NUMEX TYPE="CARDINAL">33 34</NUMEX> ] . Rofecoxib <NUMEX TYPE="CARDINAL">50</NUMEX> mg is comparable with other doses
        of oral <ENAMEX TYPE="ORGANIZATION">NSAIDs</ENAMEX> and intramuscular morphine.
        For rofecoxib <NUMEX TYPE="CARDINAL">50</NUMEX> mg this may not fully reflect its
        <ENAMEX TYPE="ORGANIZATION">efficacy</ENAMEX> compared with these other analgesics, because
        rofecoxib <NUMEX TYPE="CARDINAL">50</NUMEX> mg may have a longer duration of action. In
        the <NUMEX TYPE="CARDINAL">five</NUMEX> included trials duration was inconsistently
        reported, however, with median remedication times in <TIMEX TYPE="TIME">three</TIMEX>
        trials (but without dispersion) and percentage remedicated
        at <TIMEX TYPE="TIME">two hours</TIMEX> in <NUMEX TYPE="CARDINAL">one</NUMEX> trial and <TIMEX TYPE="TIME">24 hours</TIMEX> in <NUMEX TYPE="CARDINAL">two</NUMEX> trials. This
        disparity in reporting allowed only the crudest analysis of
        weighted mean remedication time. This was <TIMEX TYPE="TIME">1.9 hours</TIMEX> for
        <ENAMEX TYPE="PERSON">placebo</ENAMEX>, <TIMEX TYPE="TIME">7.4 hours</TIMEX> for ibuprofen <TIMEX TYPE="TIME">400 mg and 13.6 hours</TIMEX> for
        rofecoxib <NUMEX TYPE="CARDINAL">50</NUMEX> mg. The figures of <TIMEX TYPE="TIME">7.4 hours</TIMEX> for ibuprofen <NUMEX TYPE="CARDINAL">400</NUMEX>
        <ENAMEX TYPE="ORGANIZATION">mg</ENAMEX> and <TIMEX TYPE="TIME">1.9 hours</TIMEX> for placebo is in agreement with a larger
        unpublished analysis (<ENAMEX TYPE="ORGANIZATION">Barden et al</ENAMEX>, unpublished
        observations). The extended time to remedication for
        rofecoxib <NUMEX TYPE="CARDINAL">50</NUMEX> mg may represent a real clinical advantage
        where the problem is not a lack of effective analgesics,
        but rather effective analgesics ineffectively delivered [
        <NUMEX TYPE="CARDINAL">35</NUMEX> ] , and given that using a relatively large dose has no
        <ENAMEX TYPE="PERSON">disadvantages</ENAMEX>.
        The efficacy of rofecoxib in these <NUMEX TYPE="QUANTITY">five</NUMEX> classical
        clinical analgesic <ENAMEX TYPE="SUBSTANCE">assays</ENAMEX> is in contrast to <NUMEX TYPE="CARDINAL">two</NUMEX> randomized
        comparisons of rofecoxib with placebo when given before the
        operation in <ENAMEX TYPE="PER_DESC">adults</ENAMEX> [ <TIMEX TYPE="DATE">36</TIMEX> ] and <ENAMEX TYPE="PER_DESC">children</ENAMEX> [ <TIMEX TYPE="DATE">37</TIMEX> ] . The
        methodological difficulties and lack of effect of
        preemptive analgesia have been pointed out previously [ <NUMEX TYPE="CARDINAL">38</NUMEX>
        <NUMEX TYPE="CARDINAL">39</NUMEX> ] . In these <NUMEX TYPE="CARDINAL">two</NUMEX> trials additional difficulties were the
        large between-individual variation in morphine consumption
        in <ENAMEX TYPE="PER_DESC">adults</ENAMEX> [ <TIMEX TYPE="DATE">36</TIMEX> ] , and the use of a novel (unlicensed)
        syrup formulation of rofecoxib in <ENAMEX TYPE="PER_DESC">children</ENAMEX> [ <TIMEX TYPE="DATE">37</TIMEX> ] . Lack of
        a demonstrable analgesic effect in preemptive studies does
        not negate a substantial postoperative effect when patients
        both have pain and can swallow.
        There was no consistent pattern of adverse event
        reporting in the <NUMEX TYPE="CARDINAL">five</NUMEX> included trials. <NUMEX TYPE="CARDINAL">Two</NUMEX> trials had
        information on any <ENAMEX TYPE="PER_DESC">patient</ENAMEX> with any adverse event (<ENAMEX TYPE="PRODUCT">Table</ENAMEX>
        <NUMEX TYPE="CARDINAL">1</NUMEX>), with no difference between rofecoxib <NUMEX TYPE="CARDINAL">50</NUMEX> mg and placebo.
        In <NUMEX TYPE="CARDINAL">three</NUMEX> trials information on <ENAMEX TYPE="PER_DESC">patients</ENAMEX> suffering nausea
        and vomiting was available, showing that these adverse
        events occurred less frequently with rofecoxib <NUMEX TYPE="CARDINAL">50</NUMEX> mg than
        <ENAMEX TYPE="PERSON">placebo</ENAMEX>. The amount of information (number of patients
        <ENAMEX TYPE="ORGANIZATION">randomized</ENAMEX>) was insufficient to make any authoritative
        statement about adverse events, or compare the adverse
        event profile of rofecoxib <NUMEX TYPE="CARDINAL">50</NUMEX> mg in single doses with other
        single dose analgesics. Adverse events in single-dose
        studies are often poorly reported, and of limited value [
        <NUMEX TYPE="CARDINAL">40</NUMEX> ] .
        In clinical practice, <ENAMEX TYPE="ORGANIZATION">NSAIDs</ENAMEX> are associated with acute
        <ENAMEX TYPE="DISEASE">renal failure</ENAMEX> in <ENAMEX TYPE="PER_DESC">patients</ENAMEX> with impaired renal function [ <NUMEX TYPE="CARDINAL">41</NUMEX>
        <NUMEX TYPE="CARDINAL">42</NUMEX> ] and with <ENAMEX TYPE="DISEASE">congestive heart failure</ENAMEX> in older <ENAMEX TYPE="PER_DESC">people</ENAMEX> with
        a prior history of <ENAMEX TYPE="DISEASE">heart disease</ENAMEX> [ <TIMEX TYPE="DATE">43</TIMEX> ] . Acute renal
        failure after surgery occurs in <NUMEX TYPE="CARDINAL">1</NUMEX> <ENAMEX TYPE="PER_DESC">patient</ENAMEX> in <TIMEX TYPE="DATE">1000</TIMEX> after
        major surgery [ <TIMEX TYPE="DATE">44</TIMEX> ] , though it is not clear how much of
        this is specifically due to the <ENAMEX TYPE="ORGANIZATION">NSAID</ENAMEX>. For coxibs,
        especially at high doses, similar caution should be used in
        <ENAMEX TYPE="PER_DESC">patients</ENAMEX> with <ENAMEX TYPE="DISEASE">pre-existing renal</ENAMEX> or cardiac conditions as
        apply to the use of <ENAMEX TYPE="ORGANIZATION">NSAIDs</ENAMEX>. The slope of the adverse event
        dose-response may be steeper than for analgesia.
        These published reports were insufficiently detailed for
        calculation of numbers needed to treat for durations longer
        than <TIMEX TYPE="TIME">six hours</TIMEX>. Some information was available for TOTPAR
        calculated to <TIMEX TYPE="TIME">eight hours</TIMEX>, but not in a dichotomous format.
        <ENAMEX TYPE="ORGANIZATION">TOTPAR</ENAMEX> is not normally distributed, and mean values are not
        meaningful [ <TIMEX TYPE="DATE">45</TIMEX> ] . For times <TIMEX TYPE="TIME">longer than six hours</TIMEX>, and
        for duration of analgesia and adverse event profiles, more
        detailed information from individual <ENAMEX TYPE="PER_DESC">patients</ENAMEX> would be
        required.
      
      
        Conclusions
        Rofecoxib at a dose <NUMEX TYPE="CARDINAL">2</NUMEX>-<NUMEX TYPE="CARDINAL">4</NUMEX> times <TIMEX TYPE="DATE">the standard daily</TIMEX> dose
        for chronic pain is an effective single dose oral analgesic
        in acute pain. Limitations in trial reporting constrain
        conclusions about longer duration of analgesia and adverse
        event profile.
      
      
        Competing interests
        <ENAMEX TYPE="ORGANIZATION">RAM</ENAMEX> has been a <ENAMEX TYPE="PER_DESC">consultant</ENAMEX> for <ENAMEX TYPE="ORGANIZATION">MSD</ENAMEX>. <ENAMEX TYPE="ORGANIZATION">RAM & HJM</ENAMEX> have
        consulted for various pharmaceutical <ENAMEX TYPE="ORG_DESC">companies</ENAMEX>. <ENAMEX TYPE="PERSON">RAM</ENAMEX>, HJM
        <ENAMEX TYPE="ORGANIZATION">& JE</ENAMEX> have received lecture fees from pharmaceutical
        <ENAMEX TYPE="ORG_DESC">companies</ENAMEX> related to analgesics and other healthcare
        <ENAMEX TYPE="PERSON">interventions</ENAMEX>. All <ENAMEX TYPE="PER_DESC">authors</ENAMEX> have received research support
        from <ENAMEX TYPE="ORG_DESC">charities</ENAMEX>, <ENAMEX TYPE="ORG_DESC">government</ENAMEX> and industry <ENAMEX TYPE="PER_DESC">sources</ENAMEX> at various
        times, but no such support was received for this work. No
        <ENAMEX TYPE="PER_DESC">author</ENAMEX> has any direct stock holding in any pharmaceutical
        <ENAMEX TYPE="ORG_DESC">company</ENAMEX>.
      
      
        <ENAMEX TYPE="PER_DESC">Authors</ENAMEX>' contributions
        <ENAMEX TYPE="ORGANIZATION">JB</ENAMEX> was involved with searching, data extraction, quality
        <ENAMEX TYPE="PRODUCT">scoring</ENAMEX>, analysis and writing. <ENAMEX TYPE="ORGANIZATION">JE</ENAMEX> was involved with
        searching, data extraction, quality scoring and writing.
        <ENAMEX TYPE="ORGANIZATION">HJM</ENAMEX> was involved in analysis and writing. <ENAMEX TYPE="PERSON">RAM</ENAMEX> was involved
        in data extraction, quality scoring, analysis and
        writing.
      
    
  
